New Zealand markets closed

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6000+0.0300 (+1.91%)
At close: 04:00PM EDT
1.6600 +0.06 (+3.75%)
After hours: 04:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5700
Open1.5800
Bid1.5500 x 100
Ask1.7000 x 100
Day's range1.5600 - 1.7130
52-week range0.9800 - 2.5700
Volume61,667
Avg. volume277,476
Market cap44.64M
Beta (5Y monthly)0.39
PE ratio (TTM)N/A
EPS (TTM)-2.2500
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • GlobeNewswire

    NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

    Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly

  • GlobeNewswire

    NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

    BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprie

  • GlobeNewswire

    NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

    BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the w